Canaccord analyst John Newman raised the firm’s price target on ImmunoGen to $23 from $19 and keeps a Buy rating on the shares. The firm said they anticipate 2Q23 ELAHERE revenues to beat consensus of $38.7M, especially following the strong Phase 3 data at ASCO in June.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IMGN:
- ImmunoBiochem announces license and option agreement with ImmunoGen
- ImmunoGen call volume above normal and directionally bullish
- ImmunoGen put volume heavy and directionally bearish
- ImmunoGen price target raised to $21 from $15 at H.C. Wainwright
- ImmunoGen Rises on Promising Phase 3 Elahere Data in Ovarian Cancer